Mercator Therapeutics Completes $2.0M Seed Funding Round

Mercator Therapeutics, a Wellesley, Massachusetts-based biopharmaceutical company that uses in vivo phage display technology to develop novel cancer drugs, completed a $2.0m seed funding round.
Investors remained undisclosed.
The capital infusion will be used to begin to develop the company’s pipeline and to support its business development activities.
Mercator was founded to develop the research of Drs. Wadih Arap and Renata Pasqualini Lab at MD Anderson Cancer Center. In conjunction with the funding, the company has exclusively licensed rights to translate this research into novel cancer therapeutics.
Drs. Arap and Pasqualini, who are co-founders of Mercator, pioneered the use of in vivo phage display to identify targeting peptides that are believed to selectively deliver tumor-killing payloads without damaging surrounding tissue.
Other co-founders include Dr. Roy Lobb, Chairman & CSO and Mark Leuchtenberger, a member of the Board of Directors. Chris Guiffre is President and CEO.

Join the discussion